Therapeutics Weight Loss Medications Research Studies Patient Care Workforce Patient Engagement Diseases Endocrinology Health Risks Healthcare Workforce
Participants in the 26-week ADJUST-T1D trial experienced significant gains in target blood sugar range alongside substantial weight loss with weekly semaglutide.